Profarma Recalls Vermox Tablets Due to Manufacturing Deviations
Profarma Distributors LLC is recalling 254 boxes of Vermox Tablets 500 mg due to CGMP deviations. The recall is voluntary and nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II due to CGMP deviations, which typically indicates a risk of temporary or medically reversible adverse health consequences, fitting the Moderate severity criteria for voluntary precautionary recalls without reported illness.
Plain-English summary
Profarma Distributors LLC is voluntarily recalling 254 boxes of VERMOX Tablets 500 mg, 1-count box, UPC 501109900596. The recall was initiated on May 11, 2016, and is classified as Class II by the FDA. The affected product is identified by Lot # UJE 040 with an expiration date of 02/17.
The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations. The product was distributed nationwide. The recall was initiated by the firm and was terminated on January 24, 2017.
Consumers who have this product should stop using it and contact Profarma Distributors LLC for further instructions. The recall is voluntary and was initiated by the firm.
The recalled product
- Product
- VERMOX Tablets 500 mg, 1-count box, UPC 501109900596
- Manufacturer
- Profarma Distributors LLC
- Category
- Drug — Antiparasitic
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # UJE 040
- Exp. 02/17
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 5 recalled by Profarma Distributors LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · Profarma Distributors LLC
See all →- ModerateProfarma Recalls tabcin ACTIVE M.R. Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2016-06-29
- ModerateProfarma Recalls Vermox Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2016-06-29
- ModerateProfarma Recalls tabcin NOCHE Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2016-06-29
- ModerateProfarma Recalls 1% Clotrimazole Cream Due to Manufacturing Deviations
FDA (Drugs) · 2016-06-29
Same hazard · cgmp deviations
See all →- SevereBaxter Recalls Famotidine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Pantoprazole Sodium Infusion Bags Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Nexterone Amiodarone Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Dexmedetomidine Hydrochloride Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- ModerateApotex Recalls Torsemide Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2017-01-11
- ModeratePD-Rx Recalls Ibuprofen 200 mg Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2018-02-07
- ModerateVoriconazole Tablets 50mg Recalled Due to CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModerateSafecor Health Recalls Metronidazole Tablets Due to CGMP Deviations
FDA (Drugs) · 2017-06-21
- ModerateAlprazolam Tablets 1mg Recalled for CGMP Deviations
FDA (Drugs) · 2022-03-09
- ModerateFinasteride Tablets Recalled Nationwide for Manufacturing Practice Deviations
FDA (Drugs) · 2023-04-05